SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ferlay J, Bray P, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0. Lyon, France: IARC Press; 2004.
  • 2
    Anderson BO, Yip CH, Smith RA, et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer. 2008; 113: 2221-2243.
  • 3
    American Cancer Society. Cancer Facts and Figures, 2010. Atlanta, GA: American Cancer Society; 2010.
  • 4
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer Version 2.2011. Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf Accessed February 9, 2011.
  • 5
    Amir E, Seruga B, Serrano R, Ocana A. Targeting DNA repair in breast cancer: a clinical and translational update. Cancer Treat Rev. 2010; 36: 557-565.
  • 6
    Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235: 177-182.
  • 7
    Gonzalez-Angulo AM, Litton JK, Broglio KR, et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol. 2009; 27: 5700-5706.
  • 8
    Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007; 110: 965-972.
  • 9
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
  • 10
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20: 719-726.
  • 11
    Bartsch R, Wenzel C, Gampenrieder SP, et al. Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol. 2008; 62: 903-910.
  • 12
    Von Minckwitz G, du BA, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol. 2009; 27: 1999-2006.
  • 13
    Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther. 2009; 31( pt 2): 2332-2348.
  • 14
    Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355: 2733-2743.
  • 15
    Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008; 26: 5544-5552.
  • 16
    Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009; 27: 5538-5546.
  • 17
    Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010; 28: 1124-1130.
  • 18
    Baselga J, Bradbury I, Eidtmann H, et al. First Results of the NeoALTTO Trial (BIG 01-06 / EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer. Abstract presented at: Thirty-Third Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Tex. Abstract S3-3.
  • 19
    Bria E, Cuppone F, Fornier M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008; 109: 231-239.
  • 20
    Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83: 679-686.
  • 21
    Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000; 5( suppl 1): 37-44.
  • 22
    Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357: 2666-2676.
  • 23
    Miles DW, Chan A, Dirix LY, et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28: 3239-3247.
  • 24
    Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011; 29: 1252-1260.
  • 25
    Genentech. Genentech provides update on avastin for metastatic breast cancer following reviews in Europe and the United States. Available at: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=13127 Accessed December 16, 2010.
  • 26
    O'Shaughnessy J, Miles D, Gray RJ, et al. A meta-analysis of overall survival data from 3 randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MBC). J Clin Oncol. 2010; 28: 1005.
  • 27
    McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002; 62: 209-243.
  • 28
    Whenham N, D'Hondt V, Piccart MJ. HER2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies. Clin Breast Cancer. 2008; 8: 38-49.
  • 29
    Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 28: 1138-1144.
  • 30
    Gianni L, Pienkowski T, Im YH, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere'). Abstract presented at: Thirty-Third Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Tex. Abstract S3-2.
  • 31
    Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011; 29: 398-405.
  • 32
    Miller K, Gianni L, Andre F, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T) [abstract]. J Clin Oncol. 2010; 28. Abstract 1012.
  • 33
    Perez EA, Dirix L, Kocsis J, et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450G) [abstract]. Ann Oncol. 2010; 21: viii2. Abstract LBA3.
  • 34
    Roche. Roche announces positive phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. Media release, April 7, 2011. Available at: http://www.roche.com/media/media_releases/med-cor-2011-04-07b.htm Accessed April 7, 2011.
  • 35
    Murphy CG, Fornier M. HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park). 2010; 24: 410-415.
  • 36
    Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004; 96: 926-935.
  • 37
    Kaur H, Silverman P, Singh D, et al. Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2006; 24: 578s. Abstract 10623.
  • 38
    Schuler MH, Uttenreuther-Fischer MM, Piccart-Gebhart MJ, Harbeck N, on behalf of the study group and trial team. BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor, for the treatment of patients with HER2-negative metastatic breast cancer after failure of no more than 2 prior chemotherapies [abstract]. J Clin Oncol. 2010; 28. Abstract 1065.
  • 39
    Hickish T, Wheatley D, Lin N. Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res. 2009; 69: 2191-2194.
  • 40
    Gunzer K, de Mont-Serrat H, Uttenreuther-Fischer MM, Misset J, on behalf of the study group and trial team. Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy [abstract]. J Clin Oncol. 2010; 28. Abstract 1072.
  • 41
    Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010; 28: 1301-1307.
  • 42
    Lockhart AC, Rothenberg ML, Dupont J, et al. Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol. 2010; 28: 207-214.
  • 43
    Kozloff M, Chuang E, Starr A, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol. 2010; 21: 1436-1441.
  • 44
    Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008; 26: 1810-1816.
  • 45
    Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC) [abstract]. J Clin Oncol. 2010; 28: 7s. Abstract LBA1011.
  • 46
    Bergh J, Greial R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) vs D alone for the first-line treatment of advanced breast cancer (ABC) [abstract]. J Clin Oncol. 2010; 28: 7s. Abstract LBA1010.
  • 47
    Bianchi G, Loibl S, Zamagni C, et al. Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009; 20: 616-624.
  • 48
    Moreno-Aspitia A, Morton RF, Hillman DW, et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol. 2009; 27: 11-15.
  • 49
    Rugo HS, Stopeck A, Joy AA, et al. A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2007; 25. Abstract 1003.
  • 50
    Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res. 2005; 11: 3369-3376.
  • 51
    Slamon D, Gomez HL, Kabbinavar FF, et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer [abstract]. J Clin Oncol. 2008; 26: 45s. Abstract 1016.
  • 52
    Chan S, Scheulen ME, Johnston S, et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol. 2005; 23: 5314-5322.
  • 53
    Carpenter JT, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer [abstract]. J Clin Oncol. 2005; 23. Abstract 564.
  • 54
    Chow LWS, Sun Y, Jassem J. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract]. Breast Cancer Res Treat. 2006; 100: S286. Abstract 6091.
  • 55
    Ellard SL, Clemons M, Gelmon KA, et al. Randomized phase II study comparing 2 schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND. 163. J Clin Oncol. 2009; 27: 4536-4541.
  • 56
    Andre F, Campone M, O'Regan R, et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 2010; 28: 5110-5115.
  • 57
    Dalenc F, Campone M, Hupperets P, et al. Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trial [abstract]. J Clin Oncol. 2010; 28. Abstract 1013.
  • 58
    Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009; 27: 2630-2637.
  • 59
    Bachelot T, Bourgier C, Cropet C, et al. TAMRAD: a GINECO randomized phase II trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Abstract presented at: Thirty-Third Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, Tex. Abstract S1-6.
  • 60
    Papa V, Gliozzo B, Clark GM, et al. Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993; 53: 3736-3740.
  • 61
    Kaufman PA, Ferrero JM, Bourgeois H, et al. A randomized, double-blind, placebo-controlled, phase 2 study of AMG 479 with exemestane (E) or fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) metastatic (M) or locally advanced (LA) breast cancer (BC). Abstract presented at: Thirty-Third Annual San Antonio Breast Cancer Symposium; December 8-12, 2010; San Antonio, TX. Abstract S1-4.
  • 62
    Hernandez-Aya LF, Gonzalez-Angulo AM. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist. 2011; 16: 404-414.
  • 63
    Finn RS. Targeting Src in breast cancer. Ann Oncol. 2008; 19: 1379-1386.
  • 64
    Mayer E, Baurain J, Sparano J, et al. Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: phase II study CA180088 [abstract]. J Clin Oncol. 2009; 27: 43s. Abstract 1011.
  • 65
    Finn RS, Bengala C, Ibrahim N, et al. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA180059 [abstract]. Cancer Res. 2009; 69. Abstract 3118.
  • 66
    Engel RH, Brown JA, Von Roenn JH, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest. 2007; 25: 733-737.
  • 67
    Awada A, Albanell J, Canney PA, et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer. 2008; 98: 1500-1507.
  • 68
    Schmid P, Kuhnhardt D, Kiewe P, et al. A phase I/II study of bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines. Ann Oncol. 2008; 19: 871-876.
  • 69
    Modi S, Sugarman S, Stopeck A, et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC) [abstract]. J Clin Oncol. 2008; 26: 47s. Abstract 1027.
  • 70
    Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008; 14: 7138-7142.
  • 71
    Munster PN, Lacevic M, Thomas S, et al. Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy [abstract]. J Clin Oncol. 2009; 27. Abstract 1075.
  • 72
    O'Shaughnessy J, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial [abstract]. J Clin Oncol. 2009; 27: 793s. Abstract 3.
  • 73
    Bath C. Phase III results for PARP inhibitor iniparib quell optimism about new option for triple-negative metastatic breast cancer. Available at: http://www.ascopost.com/articles/march-15-2011/phase-iii-results-for-parp-inhibitor-iniparib-quell-optimism-about-new-option-for-triple-negative-metastatic-breast-cancer/ Accessed April 6, 2011.
  • 74
    Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010; 376: 235-244.
  • 75
    Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer. 1994; 74: 416-423.